Results 131 to 140 of about 67,431 (260)

CRISPR‐Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer

open access: yesMolecular Carcinogenesis, Volume 65, Issue 7, Page 874-887, July 2026.
ABSTRACT Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancer. Despite recent advances in treating BRAFV600E‐driven ATC, therapy resistance remains a significant challenge, often resulting in disease progression and death.
Shawn Noronha   +26 more
wiley   +1 more source

Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal

open access: yes, 2010
F Duffaud, S Salas, T Huyn, JL DevilleLa Timone University Hospital, Marseille, FranceAbstract: Mutations of the KIT gene are the molecular hallmark of most gastrointestinal stromal tumors (GISTs).
F Duffaud, T Huyn, et al, S Salas
core  

Enhanced PIEZO1 expression in mast cells of mastocytosis skin lesions: Relevance to Darier's sign

open access: yes
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Yoshiaki Kobayashi   +9 more
wiley   +1 more source

Benign Keratoses With Inverted Follicular Keratosis‐Like Features in a Patient Receiving Ripretinib: A Case Report

open access: yesJournal of Cutaneous Pathology, Volume 53, Issue 7, Page 586-589, July 2026.
ABSTRACT Inverted follicular keratosis (IFK) is a rare benign neoplasm of the follicular infundibulum and typically presents as a solitary, nonpigmented verrucous papule on the head and neck of older males and can mimic viral warts, basal cell carcinoma (BCC), or squamous cell carcinoma (SCC). We report a case of multiple benign keratoses with IFK‐like
Elsayed Ibrahim   +5 more
wiley   +1 more source

Imatinib-induced Gynecomastia

open access: yesIndian Journal of Endocrinology and Metabolism, 2019
Pragya Gupta   +4 more
openaire   +3 more sources

An Arterial‐Enhancing Liver Nodule With Washout in a Patient With Metabolic and Alcohol‐Associated Liver Disease

open access: yes
Journal of Gastroenterology and Hepatology, EarlyView.
Soon Kyu Lee   +2 more
wiley   +1 more source

Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer

open access: yesPigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
Integrated physical and virtual modeling provides a scalable framework to overcome sample scarcity, recapitulate mucosal melanoma biology, and accelerate translational discovery toward precision medicine. ABSTRACT Mucosal melanoma (MM) is a rare and lethal subtype of melanoma, disproportionately affecting Asian populations and exhibiting distinct ...
Xiangjie Jin   +4 more
wiley   +1 more source

Complex Surgical Decision‐Making in a Nonagenarian With Long‐Term Cancer Survivorship

open access: yes
Journal of the American Geriatrics Society, EarlyView.
Daniel Solomon   +2 more
wiley   +1 more source

Structure‐Based Design, Synthesis, and Evaluation of Novel Ponatinib Derivatives With a Significantly Altered Selectivity Profile

open access: yesChemMedChem, Volume 21, Issue 11, 15 June 2026.
We developed new derivatives of the cancer drug ponatinib, significantly reducing and altering its spectrum of target kinases. Compound 5 retained the efficacy in inhibiting the colony formation of MDA‐MB‐231 cells and acted primarily on B‐Raf and Flt‐1 as its main targets in a kinase panel.
Tobias Betzholz   +7 more
wiley   +1 more source

Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States

open access: yesChemMedChem, Volume 21, Issue 11, 15 June 2026.
Kinetic profiling of 172 compounds across KIT conformations—including D816V—reveals kinetic fingerprints that predict efficacy, selectivity, resistance, and inhibitors’ ability to stabilize key regulatory elements. Far from a secondary metric, binding kinetics provide mechanistic insights beyond affinity, offering a powerful framework for rational drug
Ana Corrionero   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy